GLOBRYTE: A Phase III, Open-label, Multicenter, Randomized Trial Evaluating Glofitamab Monotherapy in Patients with Relapsed or Refractory Mantle Cell Lymphoma

被引：0
|
作者：
Phillips, Tycel [1 ]
Matasar, Matthew [2 ]
Eyre, Toby A. [3 ]
Gine, Eva [4 ]
de L'Etang, Audrey Filezac [5 ]
Byrne, Ben [6 ]
Lundberg, Linda [5 ]
Padovani, Alejandra [5 ]
Boetsch, Christophe [5 ]
Bottos, Alessia [5 ]
Qayum, Naseer [6 ]
机构：
[1] City Hope Natl Med Ctr, Duarte, CA USA
[2] Rutgers Canc Inst New Jersey, New Brunswick, NJ USA
[3] Oxford Univ Hosp NHS Trust, Oxford, England
[4] Hosp Clin Barcelona, Barcelona, Spain
[5] F Hoffmann La Roche Ltd, Basel, Switzerland
[6] Roche Prod Ltd, Welwyn Garden City, Herts, England
来源：
CLINICAL LYMPHOMA MYELOMA & LEUKEMIA | 2024年 / 24卷
关键词：
MCL; clinical trials; non-Hodgkin lymphoma; bispecific antibody therapy; adverse events; mantle cell lymphoma; phase; 3;
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
MCL-339
引用
收藏
页码：S515 / S515
页数：1
相关论文
共 50 条
  • [41] A Phase 2, Open-Label, Multicenter Study of Tazemetostat in Combination with Rituximab for the Treatment of Relapsed or Refractory Follicular Lymphoma
    Patel, Krish
    Bailey, Neil
    Pagel, John M.
    BLOOD, 2020, 136
  • [42] Liposomal mitoxantrone monotherapy in patients with relapsed or refractory mature T-cell and natural killer-cell neoplasms: A phase 2, multicenter, open-label, single-arm trial
    Gao, Yan
    Huang, Yunhong
    Zhang, Qingyuan
    Yang, Haiyan
    Li, Yufu
    Li, Yan
    Zhou, Min
    Yang, Runxiang
    Xu, Bing
    Liu, Lihong
    Yang, Yu
    Peng, Zhigang
    Yu, Ding
    Zhou, Hui
    Zhang, Rongyan
    Zhang, Huilai
    Qi, Junyuan
    Xi, Yaming
    Xing, Xiaojing
    Wang, Zhao
    Jing, Hongmei
    Shuang, Yuerong
    Zhang, Xiaohong
    Ma, Liping
    Jin, Hongyan
    Lin, Li'e
    Li, Chunlei
    Xue, Jianfei
    Liu, Yanping
    Yuan, Jing
    Huang, Huiqiang
    CANCER, 2025, 131 (01)
  • [43] Ibrutinib as monotherapy versus combination therapy in Chinese patients with relapsed/refractory mantle cell lymphoma: A multicenter study
    Zhang, Yuchen
    Liu, Panpan
    Cai, Jun
    Jing, Hongmei
    Zou, Liqun
    Huang, Huiqiang
    Wu, Yuanbin
    Li, Wenyu
    Zhong, Liye
    Jin, Xueli
    Ye, Xu
    Feng, Ru
    Zhang, Huilai
    Zhang, Liling
    Lin, Lie
    Sun, Xiuhua
    Tian, Yuyang
    Xia, Zhongjun
    Li, Zhiming
    Huang, He
    Xia, Yi
    Cai, Qingqing
    CANCER MEDICINE, 2022, 11 (22): : 4134 - 4145
  • [44] Pirtobrutinib in Chinese patients with relapsed or refractory B-cell malignancies: A single-arm, open-label, phase 2, multicenter trial
    Liu, Yanyan
    Lin, Ningjing
    Yi, Shuhua
    Huang, Huiqiang
    Guo, Ye
    Zhang, Qingyuan
    Yang, Haiyan
    Zhang, Huilai
    Zhang, Liling
    Feng, Ru
    Qian, Yijiao
    Zhu, Jiankun
    Song, Yuqin
    Zhu, Jun
    INTERNATIONAL JOURNAL OF CANCER, 2025,
  • [45] Prophylactic Irradiation of Tracts in Patients With Malignant Pleural Mesothelioma: An Open-Label, Multicenter, Phase III Randomized Trial
    Bayman, Neil
    Appel, Wiebke
    Ashcroft, Linda
    Baldwin, David R.
    Bates, Andrew
    Darlison, Liz
    Edwards, John G.
    Ezhil, Veni
    Gilligan, David
    Hatton, Matthew
    Jegannathen, Apurna
    Mansy, Talal
    Peake, Michael D.
    Pemberton, Laura
    Rintoul, Robert C.
    Snee, Michael
    Ryder, W. David
    Taylor, Paul
    Faivre-Finn, Corinne
    JOURNAL OF CLINICAL ONCOLOGY, 2019, 37 (14) : 1200 - +
  • [46] A Multicenter, Open-Label, Single-Arm, Phase Ib Clinical Trial of HH2853 in the Treatment of Patients with Relapsed and/or Refractory Peripheral T-Cell Lymphoma
    Hong, Huangming
    Zhang, Mingzhi
    Peng, Zhigang
    Shen, Jianzhen
    Shuang, Yuerong
    Zhou, Hui
    Guo, Hongqiang
    Huang, He
    Li, Fei
    Qian, Zhengzi
    Liu, Lihong
    Wang, Liang
    Yang, Wei
    Zhang, Liling
    He, Pengcheng
    Qian, Shen
    Li, Fugen
    Li, Meng
    Lin, Tongyu
    BLOOD, 2023, 142
  • [47] Glofitamab monotherapy induces high complete response rates in patients with heavily pretreated Relapsed or Refractory (R/R) Mantle Cell Lymphoma (MCL)
    Dreyling, M.
    Phillips, T.
    Dickinson, M.
    Morschhauser, F.
    Bachy, E.
    Crump, M.
    Trneny, M.
    Bartlett, N. L.
    Zaucha, J.
    Wrobel, T.
    Offner, F.
    Humphrey, K.
    Lundberg, L.
    Relf, J.
    de L'Etang, Filezac A.
    Carlile, D.
    Byrne, B.
    Qayum, N.
    Carlo-Stella, C.
    ONCOLOGY RESEARCH AND TREATMENT, 2023, 46 : 23 - 24
  • [48] Results of an open-label multicenter phase 2 trial of lenalidomide monotherapy in refractory mycosis fungoides and Sezary syndrome
    Querfeld, Christiane
    Rosen, Steven T.
    Guitart, Joan
    Duvic, Madeleine
    Kim, Youn H.
    Dusza, Stephen W.
    Kuzel, Timothy M.
    BLOOD, 2014, 123 (08) : 1159 - 1166
  • [49] Pembrolizumab for Patients With Refractory or Relapsed Thymic Epithelial Tumor: An Open-Label Phase II Trial
    Cho, Jinhyun
    Kim, Hae Su
    Ku, Bo Mi
    Choi, Yoon-La
    Cristescu, Razvan
    Han, Joungho
    Sun, Jong-Mu
    Lee, Se-Hoon
    Ahn, Jin Seok
    Park, Keunchil
    Ahn, Myung-Ju
    JOURNAL OF CLINICAL ONCOLOGY, 2019, 37 (24) : 2162 - +
  • [50] REGOMA: A randomized, multicenter, controlled open-label phase II clinical trial evaluating regorafenib (REG) activity in relapsed glioblastoma (GBM) patients (PTS).
    Lombardi, Giuseppe
    De Salvo, Gian Luca
    Eoli, Marica
    Brandes, Alba Ariela
    Ruda, Roberta
    Faedi, Marina
    Pace, Andrea
    Lolli, Ivan
    Pasqualetti, Francesco
    Rizzato, Simona
    Germano, Domenico
    Maiello, Evaristo
    Indraccolo, Stefano
    Cabrini, Giulio
    Gardiman, Marina Paola
    Zagonel, Vittorina
    JOURNAL OF CLINICAL ONCOLOGY, 2017, 35
12345